C12N 2840/105
Enhancing translation
Official title: enhancing translation
C12N2840/105 (Enhancing translation) appears on 97 US grants and 116 published applications in this corpus.
Search patents in C12N- Granted patents
- 97
- Published applications
- 116
- Assignees
- 91
- Inventors
- 271
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 5 | 0 |
| 1997 | 8 | 0 |
| 1998 | 2 | 0 |
| 1999 | 7 | 0 |
| 2000 | 2 | 0 |
| 2001 | 4 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 4 |
| 2004 | 1 | 3 |
| 2005 | 4 | 3 |
| 2006 | 3 | 2 |
| 2007 | 2 | 2 |
| 2008 | 2 | 0 |
| 2009 | 0 | 2 |
| 2010 | 1 | 4 |
| 2011 | 0 | 2 |
| 2012 | 1 | 1 |
| 2013 | 1 | 3 |
| 2014 | 0 | 4 |
| 2015 | 3 | 7 |
| 2016 | 6 | 3 |
| 2017 | 5 | 6 |
| 2018 | 4 | 12 |
| 2019 | 1 | 10 |
| 2020 | 6 | 5 |
| 2021 | 6 | 11 |
| 2022 | 7 | 5 |
| 2023 | 3 | 3 |
| 2024 | 6 | 8 |
| 2025 | 3 | 9 |
| 2026 | 1 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Biosensors for detecting and/or neutralizing bioavailable uranium and related U-sensitive genetic molecular components, gene cassettes, vectors, genetic circuits, compositions, methods and systems10 Mar 2026US 12,571,058 B2Lawrence Livermore National Security, LLC
- RNA cleavage-induced transcript stabilizer and uses thereof25 Nov 2025US 12,480,119 B2Massachusetts Institute of Technology
- Artificial nucleic acid molecules for improved protein or peptide expression4 Nov 2025US 12,460,204 B2CureVac AG
- Methods and compositions for treating hyperoxaluria23 Sep 2025US 12,421,518 B2Tenza, Inc.
- Hepatocyte based insulin gene therapy for diabetes10 Dec 2024US 12,163,147 B2Wisconsin Alumni Research Foundation
- Multi-terminus polya polynucleotides20 Aug 2026US 2026/0241034 A1
- Artificial polynucleotide molecules for enhanced stability and translation6 Aug 2026US 2026/0226129 A1
- Utr for improving translation efficiency and/or stability of rna molecule and use thereof23 Jul 2026US 2026/0209719 A1Shenzhen Shenxin Biotechnology Co., Ltd.
- Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein11 Jun 2026US 2026/0158173 A1CureVac AG
- Hepatocyte Based Insulin Gene Therapy for Diabetes30 Apr 2026US 2026/0117250 A1Wisconsin Alumni Research Foundation
Most cited
By later US patents
- Preparation of functional human factor VIII in mammalian cells using methotrexate based selection276US 4,965,199 AGenentech, Inc. · 1990
- Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein68US 9,447,431 B2CureVac AG · 2016
- Artificial nucleic acid molecules for improved protein or peptide expression61US 9,683,233 B2CureVac AG · 2017
- Methods for the production of iPS cells using non-viral approach45US 8,546,140 B2Cellular Dynamics International, Inc. · 2013
- Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein39US 10,111,968 B2CureVac AG · 2018